ImmunityBio IBRX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
ImmunityBio (IBRX) Core Market Data and Business Metrics
Latest Closing Price
$3.05Price-Earnings Ratio
-3.32Total Outstanding Shares
853.44 Million SharesDividend
No dividendSIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
3530 John Hopkins Court, San Diego, CA, 92121
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 5,279,191 Shares | 11.28 | 3/14/2025 | 59,544,447 Shares |
| 7,589,476 Shares | 8.03 | 2/28/2025 | 60,930,572 Shares |
| 4,167,831 Shares | 13.67 | 2/14/2025 | 56,962,454 Shares |
| 8,255,797 Shares | 6.77 | 1/31/2025 | 55,923,123 Shares |
| 4,862,357 Shares | 11.22 | 1/15/2025 | 54,539,713 Shares |
| 6,280,540 Shares | 7.96 | 12/31/2024 | 50,005,639 Shares |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $375.24 Million |
| Net Cash Flow From Operating Activities, Continuing | $-421.36 Million |
| Net Cash Flow From Investing Activities, Continuing | $-19.83 Million |
| Net Cash Flow From Financing Activities | $375.24 Million |
| Net Cash Flow From Operating Activities | $-421.36 Million |
| Net Cash Flow From Investing Activities | $-19.83 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Diluted Average Shares | $2.11 Billion |
| Net Income/Loss Attributable To Noncontrolling Interest | $-86,000 |
| Net Income/Loss Available To Common Stockholders, Basic | $-587.79 Million |
| Income/Loss From Continuing Operations Before Tax | $-587.92 Million |
| Research and Development | $206.46 Million |
| Net Income/Loss Attributable To Parent | $-587.79 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-588.48 Million |
| Other Comprehensive Income/Loss | $-689,000 |
| Comprehensive Income/Loss | $-588.57 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $-86,000 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Noncurrent Assets | $201.42 Million |
| Other Current Assets | $161.19 Million |
| Inventory | $1.96 Million |
| Equity | $-744.16 Million |
| Current Assets | $163.15 Million |
| Liabilities And Equity | $364.57 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||